United States Biotechnology & Medical Research

CG Oncology Inc (CGON)

Track

Over the last 90 days, CG Oncology Inc. has seen insider activity dominated by sales, totaling $2.43 million. Director James Mule and others have engaged in multiple planned and proposed sales, with no reported purchases. This activity occurred following a Q1 2026 earnings report that missed expectations by 31.5%.
Stock chart
Ticker: CGON Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Mulay James
1 sale — total 1,138,956 USD
Planned sale 17 Apr 2026
Value US$1,876,707.73 | Price 129.20 | Shares 78,097
Proposed sale 17 Apr 2026
Value US$1,955,604.04 | Price 105.15 | Shares 10,325
Planned sale 16 Mar 2026
Value US$83,185.00 | Price 63.50 | Shares 1,310
Planned sale 16 Mar 2026
Value US$41,529.00 | Price 63.50 | Shares 654
Planned sale 9 Jan 2026
Value US$555,918.09 | Price 52.99 | Shares 10,491
Planned sale 9 Jan 2026
Value US$28,880.64 | Price 44.16 | Shares 654
Proposed sale 9 Jan 2026
Value US$549,660.37 | Price 41.93 | Shares 13,109
Planned sale 17 Nov 2025
Value US$41,430.00 | Price 41.43 | Shares 1,000
Planned sale 13 Oct 2025
Value US$43,250.00 | Price 43.25 | Shares 1,000
Planned sale 9 Oct 2025
Value US$259,672.97 | Price 43.99 | Shares 5,903
Proposed sale 9 Oct 2025
Value US$266,935.47 | Price 40.71 | Shares 6,557
Planned sale 30 Sep 2025
Value US$200,450.00 | Price 40.09 | Shares 5,000
Planned sale 29 Sep 2025
Value US$499,868.45 | Price 39.19 | Shares 12,755
Planned sale 19 Sep 2025
Value US$139,350.26 | Price 38.99 | Shares 3,574
Planned sale 18 Sep 2025
Value US$745,559.12 | Price 39.01 | Shares 19,112
Proposed sale 18 Sep 2025
Value US$1,336,834.52 | Price 37.72 | Shares 35,441
Planned sale 15 Sep 2025
Value US$35,100.00 | Price 35.10 | Shares 1,000
Proposed sale 15 Sep 2025
Value US$100,020.00 | Price 33.34 | Shares 3,000
Buy 11 Sep 2025
Value US$49,999,983.00 | Price 33.00 | Shares 1,515,151
Planned sale 5 Sep 2025
Value US$103,413.86 | Price 33.22 | Shares 3,113
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-20 2026-04-17 PlS Planned sale
Mulay James
Non-Executive Director
78,097 -35.3%
129.20
US$1,876,708 		78,097 -35.3% 129.20 US$1,876,708
2026-04-17 2026-04-17 PrS Proposed sale
JAMES MULE

Director

Non-Executive Director
10,325
105.15
US$1,955,604 		10,325 105.15 US$1,955,604
2026-03-17 2026-03-16 PlS Planned sale
Mulay James
Non-Executive Director
96,810 -35.7%
84.72
US$1,521,266 		96,810 -35.7% 84.72 US$1,521,266
2026-03-17 2026-03-16 PlS Planned sale
Mulay James
Non-Executive Director
654 -100.0%
63.50
US$41,529 		654 -100.0% 63.50 US$41,529
2026-01-13 2026-01-09 PlS Planned sale
Mulay James
Non-Executive Director
10,491 -100.0%
52.99
US$555,918 		10,491 -100.0% 52.99 US$555,918
2026-01-13 2026-01-09 PlS Planned sale
Mulay James
Non-Executive Director
654 -100.0%
44.16
US$28,881 		654 -100.0% 44.16 US$28,881
2026-01-09 2026-01-09 PrS Proposed sale
JAMES MULAY

Director

Non-Executive Director
13,109
41.93
US$549,660 		13,109 41.93 US$549,660
2025-11-18 2025-11-17 PlS Planned sale
3.1
POST LEONARD E
Non-Executive Director
1,000 -100.0%
41.43
US$41,430 		1,000 -100.0% 41.43 US$41,430
2025-10-15 2025-10-13 PlS Planned sale
3.1
POST LEONARD E
Non-Executive Director
1,000 -100.0%
43.25
US$43,250 		1,000 -100.0% 43.25 US$43,250
2025-10-10 2025-10-09 PlS Planned sale
Mulay James
Non-Executive Director
5,903 -100.0%
43.99
US$259,673 		5,903 -100.0% 43.99 US$259,673
2025-10-09 2025-10-09 PrS Proposed sale
JAMES MULAY

Director

Non-Executive Director
6,557
40.71
US$266,935 		6,557 40.71 US$266,935
2025-10-01 2025-09-30 PlS Planned sale
3.1
POST LEONARD E
Non-Executive Director
5,000 -100.0%
40.09
US$200,450 		5,000 -100.0% 40.09 US$200,450
2025-09-30 2025-09-29 PlS Planned sale
Mulay James
Non-Executive Director
12,755 -100.0%
39.19
US$499,868 		12,755 -100.0% 39.19 US$499,868
2025-09-22 2025-09-19 PlS Planned sale
Mulay James
Non-Executive Director
3,574 -100.0%
38.99
US$139,350 		3,574 -100.0% 38.99 US$139,350
2025-09-22 2025-09-18 PlS Planned sale
Mulay James
Non-Executive Director
19,112 -100.0%
39.01
US$745,559 		19,112 -100.0% 39.01 US$745,559
2025-09-18 2025-09-18 PrS Proposed sale
JAMES MULAY

Director

Non-Executive Director
35,441
37.72
US$1,336,835 		35,441 37.72 US$1,336,835
2025-09-16 2025-09-15 PlS Planned sale
3.1
POST LEONARD E
Non-Executive Director
1,000 -100.0%
35.10
US$35,100 		1,000 -100.0% 35.10 US$35,100
2025-09-15 2025-09-15 PrS Proposed sale
3.1
LEONARD E POST

Director

Non-Executive Director
3,000
33.34
US$100,020 		3,000 33.34 US$100,020
2025-09-15 2025-09-11 B Purchase
3.3
Liu Brian Guan-Chyun
Non-Executive Director
1,515,151 +inf%
33.00
US$49,999,983 		1,515,151 +inf% 33.00 US$49,999,983
2025-09-08 2025-09-05 PlS Planned sale
Mulay James
Non-Executive Director
3,113 -100.0%
33.22
US$103,414 		3,113 -100.0% 33.22 US$103,414
Explore more

More insider trading research around CG Oncology Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America